Stocks quoted in this article:
TASER International, Inc. (NASDAQ:TASR), Belo Corp. (NYSE:BLC), and BioScrip Inc. (NASDAQ:BIOS) are sitting with solid double-digit gains for 2012. But despite this technical strength -- and affordable price tags -- Wall Street couldn't care less. In fact, fewer than four analysts even bother to follow each of these stocks.
Our weekly Singles Only screen, courtesy of Schaeffer's Senior Quantitative Analyst Rocky White and Finviz.com, found these names and 26 others when searching for outperforming securities that are all-but ignored on the Street.
Eponymous electronics firm TASR has been buzzing its way higher through the latter half of 2012 and is now up more than 32% during the last 12 months. During the last three months, in fact, the stock has outperformed the S&P 500 Index (SPX) -- in terms of relative strength -- by more than 20 percentage points.
Just three analysts follow the stock, however, and this trio doesn't forecast all that much upside for TASR shares. The 12-month consensus price target (according to Thomson Reuters) is just $7.08, or 14% above the stock's current price. Elsewhere, more than 5% of the stock's float is currently sold short, laying the groundwork for a potential short-covering rally.
Analysts haven't been watching television broadcasting company BLC, as just three analysts follow the stock. Among these, one names the stock a "hold" despite its year-to-date climb of 28%. Off its early June low of $5.59, meanwhile, the shares have rocketed up roughly 45%.
BLC is expected to report earnings on October 30 and has surprised to the upside in each of the past four quarters, according to Thomson Reuters. With earnings on the horizon, short sellers have been jumping ship; short interest receded by almost 10% in the last reporting period. Still, it would take eight days to cover the remaining shorted BLC shares, more than enough ammunition for a short squeeze on any continued rallies in the shares.
Despite a year-to-date gain of nearly 75%, pharmacy service provider BIOS has almost entirely missed Wall Street's collective radar. In fact, just two firms currently follow the shares, awarding one "buy" and one "strong buy" (at least the covering analysts are optimistic).
Last week, the stock touched its highest point in two-and-a-half years, adding to its outperformance of the SPX. In the last three months, the stock has trumped the broad-market barometer by almost 33 percentage points.
Also notable is the equity's Schaeffer's Volatility Index (SVI) of 44%, which is lower than 97% of the past year's readings. This indicates BIOS options are priced relatively cheaply right now compared to the odds for a sizable move on the charts.